EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Past, Present, and Future of PSMA-Targeted Therapies in Prostate Cancer

Jasmine Anderson, Haolong Li

Serican Journal of Medicine · 07.07.2026 · 3 (3)

DOI: 10.17161/sjm.v3i3.25593 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Serican Journal of Medicine, online erschienen am 07.07.2026. Verfasst von Jasmine Anderson und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA) is a well-characterized cell-surface antigen with 100- to 1000-fold increased expression in prostate cancer relative to normal prostate tissue, establishing it as a compelling therapeutic target in metastatic castration-resistant prostate cancer (mCRPC). Decades of clinical investigation across radioligand therapy, antibody-drug conjugates (ADCs), chimeric antigen receptor T-cell (CAR-T) therapy, and bispecific T-cell engagers (BiTEs) have validated PSMA as a clinically actionable target. However, across these modalities, antigen expression heterogeneity, the immunosuppressive tumor microenvironment, and construct-level limitations have consistently emerged as the primary determinants of therapeutic outcome. The approval of ¹⁷⁷Lu-PSMA-617 (lutetium-177 vipivotide tetraxetan; Pluvicto) established proof-of-concept for PSMA-directed therapy in mCRPC, yet a substantial proportion of patients derive limited or no durable benefit, and early immunotherapeutic platforms encountered recurring challenges including cytokine release syndrome, immunogenicity, and insufficient T-cell persistence. Next-generation bispecific constructs incorporating tumor-conditional activation via molecular masking, exemplified by VIR-5500, have demonstrated markedly improved tolerability and encouraging anti-tumor activity in Phase 1 evaluation. This review traces the clinical and biological insights that have guided successive generations of PSMA-targeted therapeutic design and discusses the combination strategies and molecular profiling tools that will be essential for extending durable benefit across the broader mCRPC population.

Zitieren

APA

Anderson, J., & Li, H. (2026). The Past, Present, and Future of PSMA-Targeted Therapies in Prostate Cancer. Serican Journal of Medicine, 3(3). https://doi.org/10.17161/sjm.v3i3.25593

Vancouver

Anderson J, Li H. The Past, Present, and Future of PSMA-Targeted Therapies in Prostate Cancer. Serican Journal of Medicine. 2026;3(3). doi:10.17161/sjm.v3i3.25593

BibTeX
@article{Anderson2026,
  author = {Anderson, Jasmine and Li, Haolong},
  title = {The Past, Present, and Future of PSMA-Targeted Therapies in Prostate Cancer},
  journal = {Serican Journal of Medicine},
  year = {2026},
  volume = {3},
  number = {3},
  doi = {10.17161/sjm.v3i3.25593}
}
Kostenlos starten →